Substance / Medication

Acarbose

Overview

Active Ingredient
acarbose
RxNorm CUI
16681

Indications

Acarbose tablets, USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Labeler: Chartwell RX, LLCUpdated: 2025-12-09T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Acarbose tablets are contraindicated in patients with known hypersensitivity to the drug. Acarbose tablets are contraindicated in patients with diabetic ketoacidosis or cirrhosis. Acarbose tablets are also contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intes

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

903 trials linked to this intervention

903
Total Trials
103
Recruiting
282
With Results

Research Evidence

Published studies and systematic reviews

Sort:
The effect of acarbose on inflammatory cytokines and adipokines in adults: a systematic review and meta-analysis of randomized clinical trials.
Mohammadian Ali, Fateh Sahand Tehrani, Nikbaf-Shandiz Mahlagha et al. · Inflammopharmacology · 2024
PMID: 38170330Meta-Analysis
The effect of acarbose on lipid profiles in adults: a systematic review and meta-analysis of randomized clinical trials.
Yousefi Mohsen, Fateh Sahand Tehrani, Nikbaf-Shandiz Mahlagha et al. · BMC Pharmacol Toxicol · 2023
PMID: 37990256Meta-AnalysisFull text (PMC)
The Effects of Acarbose on Non-Diabetic Overweight and Obese Patients: A Meta-Analysis.
Yu Ai-Qing, Le Jiong, Huang Wen-Tao et al. · Adv Ther · 2021
PMID: 33421022Meta-Analysis
Acarbose for Postprandial Hypotension With Glucose Metabolism Disorders: A Systematic Review and Meta-Analysis.
Wang Biqing, Zhao Junnan, Zhan Qiuxiao et al. · Front Cardiovasc Med · 2021
PMID: 34095252Meta-AnalysisFull text (PMC)
Acarbose Monotherapy and Type 2 Diabetes Prevention in Eastern and Western Prediabetes: An Ethnicity-specific Meta-analysis.
Hu Ruijie, Li Yi, Lv Qingguo et al. · Clin Ther · 2015
PMID: 26118669Meta-Analysis
Effects of acarbose on polycystic ovary syndrome: a meta-analysis.
Zhang Y-Y, Hou L-Q, Zhao T-Y · Exp Clin Endocrinol Diabetes · 2014
PMID: 24941435Meta-Analysis
Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
Monami Matteo, Vitale Valentina, Ambrosio Maria Luisa et al. · Adv Ther · 2012
PMID: 22923161Meta-Analysis
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.
Hanefeld M, Cagatay M, Petrowitsch T et al. · Eur Heart J · 2004
PMID: 14683737Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Acarbose (substance)
SNOMED CT
386965004
UMLS CUI
C0050393
RxNorm CUI
16681
Labeler
Chartwell RX, LLC

Clinical Data

This intervention maps to 10 entities in the Healos knowledge graph.

1
Conditions
4
Biomarkers
3
Specialists
0
Symptoms
903
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Acarbose — Conditions, Biomarkers & Specialists | Healos | Healos